Results 101 to 110 of about 21,298 (206)

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Pharmacogenomics and Personalized Medicine, 2011
Vineetha Koroth Edavana1, Xinfeng Yu1, Ishwori B Dhakal1, Suzanne Williams1, Baitang Ning2, Ian T Cook3, David Caldwell1, Charles N Falany3, Susan Kadlubar11Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences ...
Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S   +8 more
doaj  

Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. [PDF]

, 2019
Accessory male breast cancer (BC) is a rare entity and is associated with poor outcome. We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation ...
Cheng, Yu, Eapen, Ann, Li, Ningjing, Mehta, Rita, Parajuli, Ritesh   +4 more
core  

Fulvestrant [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data

Cancer Management and Research, 2022
Hikmat Abdel-Razeq,1,2 Baha’ Sharaf,1 Rama AlMasri,3 Rashid Abdel-Razeq,1 Faris Tamimi,1 Omar Khader,1 Osama Salama,1 Mahmoud Abunasser,1 Sarah Edaily,1 Hazem Abdulelah1 1Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan ...
Abdel-Razeq H, Sharaf B, AlMasri R, Abdel-Razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H   +9 more
doaj  

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer

Therapeutic Advances in Medical Oncology
The landscape of breast cancer treatment continues to evolve. Survival rates have improved due to advancements in treatments such as endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and targeted therapies.
Karam Aboud, Magda Meissner, Rob Jones
doaj   +1 more source

Identification of fulvestrant analogues for estrogen receptor alpha binding in breast cancer using molecular docking and molecular dynamics simulation

Discover Chemistry
Breast cancer remains a major global health challenge, with approximately 80% of cases classified as estrogen receptor-positive (ER+). Fulvestrant, a steroidal antiestrogen and selective estrogen receptor degrader (SERD), is widely used in ER+ breast ...
Atharva Balpande, Anushka Dashputra, Nikhil Khanwani, Yashasvi Therkar, Aryan Wasewar, Ganesh C. Patil, C. Ravikumar   +6 more
doaj   +1 more source

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. [PDF]

, 2019
BackgroundPALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Diéras, Véronique, Ettl, Johannes, Finn, Richard S, Gauthier, Eric, Gelmon, Karen, Harbeck, Nadia, Joy, Anil Abraham, Lu, Dongrui R, Mori, Ave, Rugo, Hope S, Schnell, Patrick, Verma, Sunil   +11 more
core  

Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing [PDF]

, 2019
Motivation: Transcriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery.
Baldwin, Nicole E., Chan, Jinyan, Gu, Jinghua, Turner, Jacob A., Wang, Xuan   +4 more
core   +1 more source

Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant

Scientific Reports
For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors.
Scott Thomas, Elysia Roche, Pujan Desai, Nela Pawlowska, Diana Bauer, David Gingrich, Emily Hsu, Amelia N. Deitchman, Fran Aweeka, Pamela N. Munster   +9 more
doaj   +1 more source

Palbociclib-Induced Liver Failure [PDF]

, 2020
Atallah, Rami, Dingwall, Megan, Hamouche, Karl, Parker, Nathaniel, Truong, Quoc   +4 more
core   +2 more sources